X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (47) 47
humans (39) 39
oncology (39) 39
female (28) 28
lung cancer (27) 27
gefitinib (23) 23
mutation (23) 23
lung neoplasms - drug therapy (22) 22
cell line, tumor (20) 20
lung neoplasms - genetics (20) 20
animals (19) 19
cancer (18) 18
epidermal growth factor (18) 18
male (18) 18
lung neoplasms - pathology (17) 17
middle aged (17) 17
chemotherapy (16) 16
mice (16) 16
aged (15) 15
erlotinib (15) 15
tumors (15) 15
adult (14) 14
carcinoma, non-small-cell lung - drug therapy (14) 14
antineoplastic agents - pharmacology (13) 13
protein kinase inhibitors - pharmacology (13) 13
adenocarcinoma (12) 12
aged, 80 and over (12) 12
non-small cell lung cancer (12) 12
receptor, epidermal growth factor - genetics (12) 12
respiratory system (12) 12
acquired-resistance (11) 11
analysis (11) 11
carcinoma, non-small-cell lung - genetics (11) 11
egfr (11) 11
tyrosine (11) 11
antineoplastic agents - therapeutic use (10) 10
mice, nude (10) 10
quinazolines - pharmacology (10) 10
receptor, epidermal growth factor - antagonists & inhibitors (10) 10
lung cancer, non-small cell (9) 9
adenocarcinoma - genetics (8) 8
drug resistance, neoplasm - genetics (8) 8
genetic aspects (8) 8
open-label (8) 8
quinazolines - therapeutic use (8) 8
respiratory tract diseases (8) 8
t790m mutation (8) 8
afatinib (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
lung neoplasms - metabolism (7) 7
mice, transgenic (7) 7
protein kinase inhibitors - therapeutic use (7) 7
tyrosine kinase inhibitor (7) 7
cisplatin (6) 6
drug resistance, neoplasm (6) 6
epidermal growth factor receptors (6) 6
gene-mutations (6) 6
mutations (6) 6
osimertinib (6) 6
receptor, epidermal growth factor - metabolism (6) 6
risk factors (6) 6
treatment outcome (6) 6
xenograft model antitumor assays (6) 6
adenocarcinoma - pathology (5) 5
article (5) 5
bevacizumab (5) 5
clinical trials (5) 5
double-blind (5) 5
egfr mutations (5) 5
growth-factor-receptor (5) 5
immunohistochemistry (5) 5
mutation - genetics (5) 5
neoplasm staging (5) 5
nsclc (5) 5
phosphorylation (5) 5
piperidines - pharmacology (5) 5
protein-tyrosine kinase (5) 5
pulmonary/respiratory (5) 5
sensitivity (5) 5
1st-line treatment (4) 4
adenocarcinoma - drug therapy (4) 4
adenocarcinoma - metabolism (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
carboplatin (4) 4
care and treatment (4) 4
case report (4) 4
crizotinib (4) 4
disease progression (4) 4
egfr mutation (4) 4
egfr t790m (4) 4
erbb receptors - genetics (4) 4
expression (4) 4
gefitinib resistance (4) 4
gene expression (4) 4
growth (4) 4
hematology, oncology and palliative medicine (4) 4
medical colleges (4) 4
met (4) 4
metastasis (4) 4
non-small cell lung carcinoma (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences, ISSN 0027-8424, 07/2012, Volume 109, Issue 31, pp. E2127 - E2133
Journal Article
Internal Medicine, ISSN 0918-2918, 06/2019, Volume 58, Issue 11, pp. 1625 - 1627
We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor... 
Epidermal growth factor | Salvage | Epidermal growth factor receptors | Clonal deletion | Lung cancer | Case reports | Deletion | Non-small cell lung carcinoma | Mutation | Growth factors | Smoking | non-small cell lung cancer | EGFR T790M | osimertinib | Case Report | readministration
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 1955 - 11
Journal Article
Nihon rinsho. Japanese journal of clinical medicine, ISSN 0047-1852, 02/2015, Volume 73, pp. 336 - 340
Journal Article
Journal of Clinical Pathology, ISSN 0021-9746, 12/2019, p. jclinpath-2019-206204
AimsHER2-positivity pattern in the specimens of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) has been hardly reported in... 
Journal Article
Cancer Discovery, ISSN 2159-8274, 06/2011, Volume 1, Issue 1, pp. 23 - 24
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2012, Volume 2, Issue 10, pp. 922 - 933
EGFR-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKIs). The combination of EGFR-TKI afatinib and... 
lung cancer | EGFR tyrosine kinase inhibitors | afatinib | EGFR mutations | erlotinib | HER2 amplification | cetuximab | EGFR T790M | acquired resistance
Journal Article
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 06/2019, Volume 132, pp. 54 - 58
Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of ( )-mutant non-small-cell lung cancer (NSCLC). However, there... 
EGFR mutation | Non-small-cell lung cancer | Osimertinib | EGFR TKI | T790M | Re-administration | Tyrosine | Epidermal growth factor
Journal Article
Internal Medicine, ISSN 0918-2918, 2019
We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor... 
non-small cell lung cancer | EGFR T790M | osimertinib | readministration
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, p. e0121211
Background In evaluation of the clinical benefit of a new targeted agent in a phase 3 trial enrolling molecularly selected patients with advanced non-small... 
1ST-LINE TREATMENT | MULTICENTER | GEFITINIB | CISPLATIN | MULTIDISCIPLINARY SCIENCES | III TRIALS | OPEN-LABEL | TIME | AFATINIB | CHEMOTHERAPY | ERLOTINIB | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - pathology | Treatment Outcome | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Carcinoma, Non-Small-Cell Lung - mortality | Patient Selection | Clinical Trials, Phase III as Topic | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Biomarkers | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Odds Ratio | Medical research | Chemotherapy | Analysis | Medicine, Experimental | Lung cancer, Small cell | Lung cancer, Non-small cell | Cancer | Identification methods | Lung cancer | Clinical trials | Cytotoxicity | Oncology | Systematic review | Metastasis | Cancer therapies | Ethics | Epidermal growth factor | Protein-tyrosine kinase | Tyrosine | Cell survival | Hematology | Epidermal growth factor receptors | Non-small cell lung carcinoma | Survival | Patients | Medicine | Studies | Sensitivity | Hospitals | Response rates | Lymphomas | Mutation
Journal Article
Cancer Discovery, ISSN 2159-8274, 12/2013, Volume 3, Issue 12, pp. 1404 - 1415
Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine... 
CELL LUNG-CANCER | MET AMPLIFICATION | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITOR | T790M MUTATION | OPEN-LABEL | AKT INHIBITOR | GEFITINIB RESISTANCE | AXL KINASE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Drug Resistance, Neoplasm | Epithelial-Mesenchymal Transition - drug effects | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | HEK293 Cells | Female | Antineoplastic Agents - pharmacology | Acrylamides - pharmacology | Mutant Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Mice, Transgenic | Mutant Proteins - metabolism | Pyrimidines - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Acrylamides - administration & dosage | Mice, Nude | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Screening Assays, Antitumor | T790M | drug resistance | NSCLC | EMT | EGFR
Journal Article
Science Translational Medicine, ISSN 1946-6234, 07/2011, Volume 3, Issue 90, pp. 90ra59 - 90ra59
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.